importance in the field of andrology, proving to be an excellent marker of spermatogenesis and a predictive factor for the recovery of fertility in patients undergoing orchiectomy and antineoplastic treatments. 7, 8 The reference ranges for serum levels of inhibin B accepted by the international scientific community were determined on the basis of population studies of healthy men who were normozoospermic according to the semen parameters proposed by the World Health Organization (WHO).
INTRODUCTION
Inhibin is a gonadal glycoprotein hormone from the transforming growth factor-beta (TGF-β) superfamily. In adult men, it downregulates the production of follicle-stimulating hormone (FSH) by the gonadotropic cells of the anterior pituitary. 1 In males, the predominant isoform and the only one detectable in the circulation is inhibin B. 2 The main sources of inhibin B production are the Sertoli cells, which are assisted by other cell types in the assembly and secretion processes. 3 Inhibin B levels vary from infancy to puberty before reaching typical adult concentrations, with a peak in the first month of life and a trough at 6-10 years. The early postnatal rise is presumably due to activation of the hypothalamic-pituitary-gonadal (HPG) axis and reflects the proliferation of the Sertoli cells at this time. In prepuberty, its levels are independent of the presence of actively proliferating germ cells and rise under the stimulation of FSH. After puberty, inhibin B secretion is mainly controlled by spermatogenesis. 4 Baseline inhibin B levels are defined at the point that Sertoli cell proliferation ends and spermatogenesis begins and can be considered as a marker of Sertoli cell density.
The positive correlation of serum inhibin B levels, spermatogenesis, and testicular volume is a clearly demonstrated concept in the literature. 5, 6 In recent years, inhibin B has assumed particular ORIGINAL ARTICLE Inhibin B: are modified ranges needed for orchiectomised testicular cancer patients?
patients without children at the time of diagnosis. 17 Most studies show that spermatogenesis is already affected in testicular cancer (TC) patients at the time of diagnosis, in comparison with both the healthy population and patients with other types of cancer. The reduction in sperm number is accompanied by changes to the HPG axis, with a rise in FSH and luteinizing hormone (LH) and a drop in inhibin B, while testosterone levels are essentially unaffected. [18] [19] [20] The measurement of FSH and inhibin B levels are complementary tools in andrological diagnostics and the assessment of male reproductive health. This study thus proposes to investigate inhibin B levels in TC patients who have undergone unilateral orchiectomy, in order to identify a minimum value representative of normal semen quality.
PARTICIPANTS AND METHODS

Study participants
The study was approved by Ethical Committee "Sapienza" University, Policlinico Umberto I, Rome, Italy. Written informed consent was obtained from all study participants. We conducted a retrospective study on 290 patients attending the Seminology Laboratory Sperm Bank at the Sapienza University of Rome's Department of Experimental Medicine, Medical Pathophysiology Section, between January 2012 and November 2015 for cryopreservation of seminal fluid following a diagnosis of testicular cancer (TC group). Only patients with a normal total sperm number according to the WHO 2010 reference parameters 9 were selected, to ensure that the serum inhibin B levels measured were representative of normozoospermia. All patients underwent semen examination and hormone assay on the day of cryopreservation, i.e., 1 month after the orchiectomy and before beginning antineoplastic therapy. This was a single-center study. All hormone and semen analyses were carried out in the seminology and hormone laboratories of our department. The study also included a control group of 117 healthy, normozoospermic men attending our center for an andrological checkup (CTR group). Participants with sperm concentration <39 × 10 6 ml −1 , previous anabolic steroid use, other andrological diseases affecting semen quality, hypogonadotropic hypogonadism, Klinefelter syndrome or other genetic or chromosomal disorders, and other extragonadal neoplastic diseases were excluded from the study. (testosterone), respectively. Serum concentrations of inhibin B were measured by enzyme-linked immunosorbent assay (ELISA; GEN II, Beckman Coulter laboratories, Brea, CA, USA). The detection limit was 7.0 pg ml −1 and the intra-and inter-assay coefficients of variation were 3.1% and 6.8%, respectively, at 126 pg ml −1 . The normal postpubertal range was 80-350 pg ml −1 . Semen samples were collected by masturbation directly into a sterile plastic container after 2-7 days of sexual abstinence and examined by optical microscope (Leica DM5000B, Leica Microsystems, Wetzlar, Germany) according to the WHO criteria (2010). 9 The following variables were assessed: sperm concentration (×10 6 ml −1 ), total sperm number (×10 6 per ejaculate), progressive motility (%), and morphology (% abnormal forms).
Evaluation of patients
Statistical analyses
Continuous variables are presented as mean ± standard deviation (s.d.) or median and quartiles; categorical variables are summarized with count and percentage. Differences were evaluated by the Student's t-test or Mann-Whitney U test, depending on the shape of the distribution curve. The normality of the distribution curve was evaluated using the Kolmogorov-Smirnov test. The correlation coefficients among the variables considered were evaluated using Pearson's or Spearman's test, where appropriate. The probability values are two-sided; P < 0.05 was considered to indicate statistical significance. All computations were carried out with the SPSS 24.0 (SPSS Inc., Chicago, IL, USA). Table 1 ). There was a statistically significant difference between the two groups in all semen parameters (all P < 0.05, Table 1 ). Apart from SHBG (P = 0.088), there was a statistically significant difference between the two groups in the levels of all hormones (all P < 0.001, Table 2 ).
RESULTS
Correlations of gonadotropin, inhibin B, and semen parameters were performed for the TC group. Table 3 shows the correlation coefficient values and their significance obtained using Spearman's test. There was a positive correlation between log of absolute values of inhibin B and total sperm number and no correlation with progressive motility (Figure 1a and 1b) . Then we found a negative correlation between log of absolute values of gonadotropin and total sperm number and progressive motility (Figure 1c and 1d) . Moreover, multivariate analysis showed a significant association between inhibin B levels and total sperm number (P = 0.008) but not sperm progressive motility (P = 0.802); on the contrary, FSH was significantly associated with progressive motility (P = 0.009) but not with total sperm number (P = 0.162) in this particular group of patients. To identify an inhibin B cutoff value corresponding to normal spermatogenesis, the percentile distribution of gonadotropin and inhibin B values in the CTR group was analyzed ( Table 4 ). The 5 th percentile of the CTR group was taken as the cutoff (62.75 pg ml −1 ). The same analysis was then carried out for the TC group ( 
DISCUSSION
The clinical role of inhibin B
Literature evidence suggests that spermatogenesis in TC patients is already impaired at the time of diagnosis, with worsening of semen parameters after removal of the affected testicle. 18 It can thus be hypothesized that impairment of spermatogenesis is not solely due to the direct effect of the cancer but is part of a preexisting gonadal dysgenesis syndrome which also affects the contralateral testicle. Testicular tumors potentially affect fertility by impairing spermatogenesis through a mechanism involving destruction of the surrounding tissue, local secretion of human chorionic gonadotropin (HCG) and other paracrine factors, elevation of intrascrotal temperature, and modification of the local blood flow. [21] [22] [23] [24] In addition to their decline in semen quality, TC patients who have undergone unilateral orchiectomy also present HPG axis modifications, with a rise in FSH and (to a lesser extent) LH and a drop in serum inhibin B concentration. Using inhibin B as a marker of semen quality, Isaksson et al. 8 demonstrated that all participants with inhibin B >56 pg ml −1 12 months after the end of antineoplastic therapy maintained good semen quality at 3 years, while lower values were predictive of the risk of azoospermia. The authors thus proposed evaluation of inhibin B at 1 year after chemo-or radiotherapy as a single, reliable marker of semen quality and recovery of spermatogenesis in TC patients. The inhibin B reference ranges used internationally derive from population studies of cohorts with heterogeneous conditions. It should be stressed that most of these studies used immunoenzymatic methods which are no longer available and which suffered from poor inter-measurement precision and accuracy. The immunoenzymatic methods in use today are more refined and specific. Klingmüller and Haidl, 10 in 1997, were the first authors to suggest a cutoff below which the inhibin B value was predictive of impaired spermatogenesis, on the basis of inhibin B levels above 112 pg ml −1 seen in all normozoospermic patients taken into consideration. In 1998, Jensen et al. 11 identified 80 pg ml −1 as the lower reference value: below this cutoff, there was a 100% chance of having sperm concentration below 20 × 10 6 ml −1 . The reference values used have changed over the years. In 2005, Sikaris et al. 12 proposed a lower reference limit of 48 pg ml −1 , in contrast with Andersson et al. 's 13 proposal of 105 pg ml −1 in 2004. This remarkable difference could be due to differences in the study populations (ethnic and geographic origin), the inclusion criteria used, and the methodologies. Barbotin et al. 25 recently conducted a population study with the aim of defining the concentration and reference ranges of serum inhibin B levels in normozoospermic men based on the WHO's 2010 semen parameters. That study investigated two groups, one of healthy normozoospermic participants and one with at least one impaired semen parameter. The reference range was proposed on the basis of values corresponding to the 2.5 th and 97.5 th percentile of the inhibin B values in the normozoospermic group, corresponding to 92 pg ml −1 and 316 pg ml −1 , respectively. An inhibin B level <92 pg ml −1 was associated with increased risks of total sperm number below 39 × 10 6 ml −1 (odds ratio [OR]: 16.93, 95% confidential interval [CI]: 9.82-29.18), asthenozoospermia, and teratozoospermia. 24 There are fewer literature reports of inhibin B levels in patients who have undergone unilateral orchiectomy for causes other than cancer (such as cryptorchidism and testicular trauma), and most studies are based on animal models.
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Inhibin B levels in our cohort of testicular cancer patients The present study investigated the hormone and semen profile of 290 testicular cancer patients 1 month after unilateral orchiectomy and before beginning any antineoplastic treatment. This observation time was chosen to avoid any treatment-induced impairment of testicular function. Our data are consistent with literature evidence, in which we found a negative correlation between serum inhibin B and FSH levels, a positive correlation between inhibin B and total sperm number, and a negative correlation between FSH and total sperm number in both groups. The correlation coefficient values seem to confirm that inhibin B is superior to FSH as a predictive factor of normal spermatogenesis. 27 A strong point of our study is its single-center nature. We analyzed the semen parameters and hormone profile of a large caseload of testicular cancer orchiectomised patients in the same laboratory, thus considerably reducing the variability of the results. Inhibin B values were analyzed to evaluate the minimum value still associated with normal semen quality, selecting only normozoospermic patients according to the WHO 2010 parameters. Enrollment was limited to monorchidic patients with semen parameters within the WHO's 2010 reference ranges. Since inhibin B is a quantitative marker of spermatogenesis, this recruitment was carried out in order to identify the minimum value of inhibin B still representative of normal semen quality. To our knowledge, this information has never been previously reported, despite its importance in the counseling of cancer patients in order to correctly interpret semen and hormone parameters and assess testicular function. In our study, approximately 68.6% (199/290) of our normozoospermic postorchiectomy TC patients had gonadotropin values within the normal reference range, comprising the 95 th percentile of the control group (FSH ≤7.6 mIU ml −1 ). However, the remaining 31.4% presented an elevated FSH value, despite a semen quality within the reference limits. Our study revealed the poor sensitivity of the current inhibin B reference range when applied to monorchidic patients. While the literature values are heterogeneous, they identified a lower reference limit of between 80 pg ml −1 and 112 pg ml −1 for inhibin B. [10] [11] [12] These values refer to a population of healthy men selected on the basis of a sperm concentration of >20 × 10 6 ml −1 and a total sperm number of ≥39 
